conv.

All stories
HealthQuiet · 41h

Roche's obesity drug shows 15.5% weight loss in mid-stage diabetes trial

Swiss drugmaker advances competitor to market leaders Eli Lilly and Novo Nordisk with once-weekly GLP-1/GIP injection.

newest coverage 1d agosummary written 1d ago4 pieces NewswiresGoogle News

What to know

  • Roche's enicepatide delivered 15.5% average weight loss and improved blood sugar control in mid-stage diabetes trial, with mild-to-moderate side effects in 2% of patients.
  • The once-weekly GLP-1/GIP injection positions Roche to challenge market leaders Eli Lilly and Novo Nordisk in the fast-growing obesity drug category.
  • Roche previously reported 22.7% weight loss in non-diabetic patients and plans late-stage trials starting in first half of 2027.
  • Competitors AstraZeneca and Amgen are also pursuing obesity drug approvals in a market being redefined by GLP-1 agonists.

“Swiss drugmaker Roche announced Tuesday that its experimental obesity treatment helped patients with type 2 diabetes reduce blood sugar levels and lose an average 15.5% of their body weight in a mid-stage trial.”

Investing.com · Investing.com News ↗

Roche Swiss pharmaceutical companyEli LillyEli Lilly Obesity drug market leaderNovo Nordisk Obesity drug market leaderAstraZeneca Competing obesity drug developerAmgen Competing obesity drug developer

Roche's obesity drug shows 15.5% weight loss in mid-stage diabetes trial
Investing.com News

How it unfolded 2 developments, newest first · click a bar or a number to jump articles

Peak 2 pieces in one hour at Sep 22, 12 AM; 4 pieces over 2 days (4 articles) Sep 22, 12 AM — 2 pieces · 2 articles — Google News 2Sep 22, 1 AM — quietSep 22, 2 AM — quietSep 22, 3 AM — quietSep 22, 4 AM — quietSep 22, 5 AM — 1 piece · 1 article — Newswires 1Sep 22, 6 AM — 1 piece · 1 article — Newswires 1Sep 22, 7 AM — quietSep 22, 8 AM — quietSep 22, 9 AM — quietSep 22, 10 AM — quietSep 22, 11 AM — quietSep 22, 12 PM — quietSep 22, 1 PM — quietSep 22, 2 PM — quietSep 22, 3 PM — quietSep 22, 4 PM — quietSep 22, 5 PM — quietSep 22, 6 PM — quietSep 22, 7 PM — quietSep 22, 8 PM — quietSep 22, 9 PM — quietSep 22, 10 PM — quietSep 22, 11 PM — quietYesterday, 12 AM — quietYesterday, 1 AM — quietYesterday, 2 AM — quietYesterday, 3 AM — quietYesterday, 4 AM — quietYesterday, 5 AM — quietYesterday, 6 AM — quietYesterday, 7 AM — quietYesterday, 8 AM — quietYesterday, 9 AM — quietYesterday, 10 AM — quietYesterday, 11 AM — quietYesterday, 12 PM — quietYesterday, 1 PM — quietYesterday, 2 PM — quietYesterday, 3 PM — quietYesterday, 4 PM — quietYesterday, 5 PM — quietYesterday, 6 PM — quietYesterday, 7 PM — quietYesterday, 8 PM — quietYesterday, 9 PM — quietYesterday, 10 PM — quietYesterday, 11 PM — quiet 12
8 AM4 PMyesterday8 AM4 PMnow · 12:57 AM ET
  1. 2

    Roche plans late-stage trials for 2027

    Roche announced plans to begin late-stage glycemic-control and cardiovascular outcomes studies in the first half of 2027, advancing enicepatide toward potential approval.

  2. 1

    Roche announces diabetes trial results: 15.5% weight loss, improved blood sugar control

    Roche reported that enicepatide achieved 15.5% average body weight loss and met primary endpoints for blood sugar control in a 447-patient mid-stage trial. About 62% of patients achieved non-diabetic HbA1c levels, with side effects mostly mild to moderate.

    1. 2 outlets Roche GLP-1 delivers 16% weight loss in mid-stage trial

      first by Seeking Alpha, 1d ago · also Investing.com News

      1 more headline
    2. 2 outlets Roche Obesity Shot Cuts Body Weight 15.5% in Mid-Stage Trial

      first by Bloomberg.com, 1d ago · also Reuters

      1 more headline
  3. background

    Roche reports 22.7% weight loss in non-diabetic obesity trial — Roche disclosed that enicepatide helped overweight or obese patients without diabetes lose 22.7% of body weight in a separate mid-stage trial.